China Vaccine Contract Manufacturing Market Size & Outlook
China vaccine contract manufacturing market, 2018-2030 (US$M)
Related Markets
China vaccine contract manufacturing market highlights
- The China vaccine contract manufacturing market generated a revenue of USD 361.4 million in 2023 and is expected to reach USD 502.7 million by 2030.
- The China market is expected to grow at a CAGR of 4.8% from 2024 to 2030.
- In terms of segment, attenuated vaccine was the largest revenue generating vaccine type in 2023.
- DNA Vaccines is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Vaccine contract manufacturing market data book summary
| Market revenue in 2023 | USD 361.4 million |
| Market revenue in 2030 | USD 502.7 million |
| Growth rate | 4.8% (CAGR from 2023 to 2030) |
| Largest segment | Attenuated vaccine |
| Fastest growing segment | DNA Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
| Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
Other key industry trends
- In terms of revenue, China accounted for 8.6% of the global vaccine contract manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, India vaccine contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 598.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Contract Manufacturing Market Scope
Vaccine Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China vaccine contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 29.61% in 2023. Horizon Databook has segmented the China vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
China is a cost-effective market for vaccine contract manufacturing. Moreover, Chinese CMOs adhere to cGMP standards and have improved regulatory oversight, which ensures superior quality. Thus, increasing demand for superior quality and ongoing advancements in the pharmaceutical sector are expected to continue driving the vaccine contract manufacturing market in China.
Some of the key companies providing vaccine contract manufacturing for pharmaceuticals in China are Catalent, Inc. and Lonza. The expansion of key players in China's vaccine contract manufacturing market has positively impacted their service quality, ensuring that manufactured products meet the highest quality and safety standards.
Reasons to subscribe to China vaccine contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China vaccine contract manufacturing market databook
-
Our clientele includes a mix of vaccine contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into China vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China vaccine contract manufacturing market size, by vaccine type, 2018-2030 (US$M)
China Vaccine Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
